BR112016017012A2 - Ensaio de potência para agentes terapêuticos - Google Patents

Ensaio de potência para agentes terapêuticos

Info

Publication number
BR112016017012A2
BR112016017012A2 BR112016017012A BR112016017012A BR112016017012A2 BR 112016017012 A2 BR112016017012 A2 BR 112016017012A2 BR 112016017012 A BR112016017012 A BR 112016017012A BR 112016017012 A BR112016017012 A BR 112016017012A BR 112016017012 A2 BR112016017012 A2 BR 112016017012A2
Authority
BR
Brazil
Prior art keywords
therapeutic agents
potency test
cells
determining
therapeutic agent
Prior art date
Application number
BR112016017012A
Other languages
English (en)
Inventor
Healey Don
West COLLISON Lauren
Original Assignee
Opexa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opexa Therapeutics Inc filed Critical Opexa Therapeutics Inc
Publication of BR112016017012A2 publication Critical patent/BR112016017012A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

ENSAIO DE POTÊNCIA PARA AGENTES TERAPÊUTICOS. São aqui proporcionados métodos para determinar o potencial tolerogênico de um agente terapêutico compreendendo determinar a capacidade de o agente terapêutico aumentar a expressão de marcadores tolerogênicos, por exemplo, PD-L1, por células de apresentação de antígeno, tal como monócitos, macrófagos, células B e células dendríticas.
BR112016017012A 2014-01-24 2015-01-23 Ensaio de potência para agentes terapêuticos BR112016017012A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931470P 2014-01-24 2014-01-24
PCT/US2015/012776 WO2015112913A1 (en) 2014-01-24 2015-01-23 Potency assay for therapeutic agents

Publications (1)

Publication Number Publication Date
BR112016017012A2 true BR112016017012A2 (pt) 2017-08-08

Family

ID=52450646

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016017012A BR112016017012A2 (pt) 2014-01-24 2015-01-23 Ensaio de potência para agentes terapêuticos

Country Status (10)

Country Link
US (1) US20170241979A1 (pt)
EP (1) EP3097208A1 (pt)
JP (1) JP2017506332A (pt)
CN (1) CN105960468A (pt)
AU (1) AU2015209158A1 (pt)
BR (1) BR112016017012A2 (pt)
CA (1) CA2937385A1 (pt)
IL (1) IL246817A0 (pt)
MX (1) MX2016009629A (pt)
WO (1) WO2015112913A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
CA2239957A1 (en) 1995-12-22 1997-07-03 Abbott Laboratories Fluorescence polarization immunoassay diagnostic method
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
WO2013184976A2 (en) * 2012-06-06 2013-12-12 Northwestern University Compositions and methods for antigen-specific tolerance

Also Published As

Publication number Publication date
CA2937385A1 (en) 2015-07-30
JP2017506332A (ja) 2017-03-02
MX2016009629A (es) 2017-02-13
CN105960468A (zh) 2016-09-21
EP3097208A1 (en) 2016-11-30
WO2015112913A1 (en) 2015-07-30
IL246817A0 (en) 2016-08-31
AU2015209158A1 (en) 2016-08-04
US20170241979A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
AU2024202345A1 (en) Nucleic acid carriers and therapeutic methods of use
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
CO2017001573A2 (es) Receptor quimérico de antígeno anti-cd123
BR112015021410A2 (pt) inibidores macrocíclicos das interações das proteína/proteína pd-1/pd-l1 e cd80(b7-1)/pd-l1
PH12017500441A1 (en) Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
BR112018005937A2 (pt) conjugados de oligonucleotídeo de afinidade e usos destes
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
CL2016002375A1 (es) Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina y métodos que usan los mismos
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
MY191539A (en) Streptococcal vaccine
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
DOP2016000073A (es) Composiciones y métodos para inhibir la expresión del gen alas1
CO2017001626A2 (es) Anticuerpo anti-orai1
MX360084B (es) Composicion de champu que comprende matriz de gel e histidina.
MY180166A (en) Cosmic quenchers
BR112017005666A2 (pt) micropartículas injetáveis para liberação hiper-localizada de agentes terapêuticos
BR112017001888A2 (pt) formulações biológicas para instilação intravesical
MX2022010827A (es) Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados.
MX2017005700A (es) Composiciones de microesferas de gas encapsuladas en lipidos y metodos relacionados.
MX2015016490A (es) Esteres sulfatados de acidos oligohidroxicarboxilicos, y uso de los mismos.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]